Research & Development

We strengthen our technological research and innovation capabilities,
improve product quality and market competitiveness,
and achieve sustainable development.

Behind the Success of cyclodextrin excipient Development

We make cyclodextrin excipient development easy based on our strong R&D strength.

Take a Tour on Our Lab

Guaranteed quality and safe use are the first priorities of our laboratory.

p052-s03-img

R&D Achievements

Hydroxypropyl beta cyclodextrin and sulfobutyl beta cyclodextrin sodium have been registered with the FDA and successfully registered with the CDE. Hydroxypropyl beta cyclodextrin oral registration number F20209990366 (status “A”), injection registration number F20180001469, sulfobutyl beta cyclodextrin sodium CDE registration number F20190000285 (status “A”), methyl beta cyclodextrin CDE registration number F20210000272, and hydroxypropyl gamma cyclodextrin CDE registration number F20220000042.

Leading Manufacture And Solution Provider Of Cyclodextrin Derivatives